Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02155829 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Riluzole to Treat Post-traumatic Stress Disorder (PTSD)
A Phase 1 study, sponsored by Uniformed Services University of the Health Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT02155829 is a Phase 1 study that has completed, run by Uniformed Services University of the Health Sciences. The registered enrollment target is 75 participants.
The verdict
NCT02155829, a Phase 1 study, has completed, sponsored by Uniformed Services University of the Health Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Riluzole is effective in the augmentation treatment of post-traumatic stress disorder (PTSD) that is experienced by Active Duty military service members and Operation Enduring Freedom (OEF), Operation Iraqi Freedom (OIF), and Operation New Dawn (OND) veterans who have not had symptom reduction after one or more kinds of medications or therapies.
Interventions
- DRUG Riluzole
- DRUG Placebo (for Riluzole)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2013-07 |
| Est. Completion | 2017-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02155829
The ClinicalTrials.gov registry entry for NCT02155829 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Uniformed Services University of the Health Sciences, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Riluzole is the first listed.
NCT02155829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02155829 about?
NCT02155829 is a clinical study titled "Safety Study of Riluzole to Treat Post-traumatic Stress Disorder (PTSD)". The purpose of this study is to determine whether Riluzole is effective in the augmentation treatment of post-traumatic stress disorder (PTSD) that is experienced by Active Duty military service members and Operation Enduring Freedom (OEF), Operation Iraqi Freedom (OIF), and Operation New Dawn (OND)...
What is the current status of trial NCT02155829?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2013-07. Estimated completion is 2017-11-30.
What interventions are being tested in trial NCT02155829?
The interventions under investigation include: Riluzole (DRUG), Placebo (for Riluzole) (DRUG).
Who is sponsoring clinical trial NCT02155829?
This trial is sponsored by Uniformed Services University of the Health Sciences, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.